EP4126222A1 — Inhibitors of c5a for the treatment of corona virus infection
Assigned to InflaRx GmbH · Expires 2023-02-08 · 3y expired
What this patent protects
The present invention relates to an inhibitor of C5a activity medical condition caused by or associated with infection with a corona virus. The invention also relates to the use of an inhibitor of C5a activity in the reduction of an inflammatory response in a subject suffering fr…
USPTO Abstract
The present invention relates to an inhibitor of C5a activity medical condition caused by or associated with infection with a corona virus. The invention also relates to the use of an inhibitor of C5a activity in the reduction of an inflammatory response in a subject suffering from a corona virus infection. The invention further relates to an inhibitor of C5a activity for use in the improvement of organ function, in particular lung function and/or hepatic function, in a subject suffering from a corona virus infection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.